|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPL28 |
Gene summary for RPL28 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPL28 | Gene ID | 6158 |
| Gene name | ribosomal protein L28 | |
| Gene Alias | L28 | |
| Cytomap | 19q13.42 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P46779 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6158 | RPL28 | CA_HPV_3 | Human | Cervix | CC | 5.94e-06 | -7.55e-02 | 0.0414 |
| 6158 | RPL28 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 7.81e-04 | 9.67e-02 | 0.0208 |
| 6158 | RPL28 | CCI_1 | Human | Cervix | CC | 1.59e-74 | -2.09e+00 | 0.528 |
| 6158 | RPL28 | CCI_2 | Human | Cervix | CC | 2.54e-77 | -1.74e+00 | 0.5249 |
| 6158 | RPL28 | CCI_3 | Human | Cervix | CC | 5.27e-85 | -2.10e+00 | 0.516 |
| 6158 | RPL28 | CCII_1 | Human | Cervix | CC | 6.27e-118 | -2.06e+00 | 0.3249 |
| 6158 | RPL28 | H2 | Human | Cervix | HSIL_HPV | 3.51e-39 | -3.00e-01 | 0.0632 |
| 6158 | RPL28 | L1 | Human | Cervix | CC | 3.64e-05 | -2.04e-01 | 0.0802 |
| 6158 | RPL28 | T1 | Human | Cervix | CC | 3.22e-06 | -1.65e-01 | 0.0918 |
| 6158 | RPL28 | T2 | Human | Cervix | CC | 6.83e-05 | -2.15e-01 | 0.0709 |
| 6158 | RPL28 | T3 | Human | Cervix | CC | 9.71e-03 | -3.77e-02 | 0.1389 |
| 6158 | RPL28 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.63e-64 | 1.36e+00 | 0.0155 |
| 6158 | RPL28 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.55e-51 | 2.20e+00 | -0.1808 |
| 6158 | RPL28 | HTA11_2951_2000001011 | Human | Colorectum | AD | 9.16e-34 | 2.55e+00 | 0.0216 |
| 6158 | RPL28 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.32e-48 | 1.97e+00 | -0.0811 |
| 6158 | RPL28 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.95e-21 | 9.40e-01 | -0.1088 |
| 6158 | RPL28 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.57e-72 | 2.17e+00 | -0.1954 |
| 6158 | RPL28 | HTA11_411_2000001011 | Human | Colorectum | SER | 6.60e-23 | 2.68e+00 | -0.2602 |
| 6158 | RPL28 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.38e-15 | 1.98e+00 | -0.2196 |
| 6158 | RPL28 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.41e-39 | 2.12e+00 | -0.1207 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
| GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
| GO:00021815 | Colorectum | CRC | cytoplasmic translation | 70/2078 | 148/18723 | 1.53e-28 | 9.16e-25 | 70 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:000218132 | Liver | Cyst | cytoplasmic translation | 70/496 | 148/18723 | 9.01e-71 | 3.85e-67 | 70 |
| GO:00021818 | Lung | IAC | cytoplasmic translation | 85/2061 | 148/18723 | 3.11e-43 | 1.85e-39 | 85 |
| GO:000218113 | Lung | AIS | cytoplasmic translation | 85/1849 | 148/18723 | 5.48e-47 | 3.19e-43 | 85 |
| GO:000218123 | Lung | AAH | cytoplasmic translation | 64/613 | 148/18723 | 1.74e-55 | 7.99e-52 | 64 |
| GO:000218133 | Lung | MIAC | cytoplasmic translation | 73/967 | 148/18723 | 4.84e-54 | 2.48e-50 | 73 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa03010 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030101 | Colorectum | AD | Ribosome | 96/2092 | 167/8465 | 8.28e-20 | 5.54e-18 | 3.54e-18 | 96 |
| hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
| hsa030102 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030103 | Colorectum | SER | Ribosome | 92/1580 | 167/8465 | 2.21e-26 | 3.66e-24 | 2.66e-24 | 92 |
| hsa051713 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
| hsa030104 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051714 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| hsa030105 | Colorectum | MSS | Ribosome | 96/1875 | 167/8465 | 1.82e-23 | 2.03e-21 | 1.24e-21 | 96 |
| hsa051715 | Colorectum | MSS | Coronavirus disease - COVID-19 | 108/1875 | 232/8465 | 6.50e-17 | 1.67e-15 | 1.03e-15 | 108 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPL28 | insertion | In_Frame_Ins | novel | c.93_94insCCCATCTCTACTAAAAATACAAAAAAT | p.Asn31_Leu32insProIleSerThrLysAsnThrLysAsn | p.N31_L32insPISTKNTKN | P46779 | protein_coding | TCGA-AO-A03P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | letrozole | PD | ||
| RPL28 | SNV | Missense_Mutation | novel | c.430N>T | p.Arg144Cys | p.R144C | P46779 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RPL28 | SNV | Missense_Mutation | c.313G>A | p.Asp105Asn | p.D105N | P46779 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| RPL28 | SNV | Missense_Mutation | c.239C>A | p.Thr80Asn | p.T80N | P46779 | protein_coding | deleterious(0.03) | possibly_damaging(0.472) | TCGA-AY-A8YK-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | CR | |
| RPL28 | SNV | Missense_Mutation | c.40T>C | p.Ser14Pro | p.S14P | P46779 | protein_coding | deleterious(0.01) | possibly_damaging(0.804) | TCGA-CM-5860-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | SD | |
| RPL28 | SNV | Missense_Mutation | c.157C>T | p.Pro53Ser | p.P53S | P46779 | protein_coding | deleterious(0.04) | benign(0.114) | TCGA-AG-A01W-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| RPL28 | SNV | Missense_Mutation | novel | c.233T>C | p.Val78Ala | p.V78A | P46779 | protein_coding | tolerated(0.31) | benign(0.372) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RPL28 | SNV | Missense_Mutation | novel | c.260N>A | p.Arg87His | p.R87H | P46779 | protein_coding | deleterious(0.02) | possibly_damaging(0.694) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPL28 | SNV | Missense_Mutation | novel | c.436N>A | p.Asp146Asn | p.D146N | P46779 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPL28 | SNV | Missense_Mutation | novel | c.200N>A | p.Arg67Lys | p.R67K | P46779 | protein_coding | tolerated(0.44) | benign(0.212) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |